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slag, 2006), neurocognitive functioning (COG scale) (Macken-
zie, 2002), and Beck Depression Inventory (Findler, 2001).
CONCLUSION: There is evidence to suggest that the PF Scale
of the SF-36 is reliable, as measured by internal consistency, and
valid, as measured by discriminant and concurrent validity.
SKIN—Cost Studies
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OBJECTIVES: New BA offer more therapeutic options to
control psoriasis symptoms but add to the already considerable
cost of managing psoriasis. Expert panels have published guide-
lines for the use of BA although few of them considered the treat-
ment options cost-effectiveness. The Brazilian expert guidelines,
however, considered. We present a Brazilian cost effectiveness
model based on micro-simulation. METHODS: Our cost effec-
tiveness model simulates the real-life Brazilian treatment
sequence (acitretin, methotrexate, cyclosporine, BA) for 1000
patients based on the average time of use of each drug (10.74,
6.56, 24.00, and 30.00 months, respectively). Three different
BA, adalimumab, eternacept and inﬂiximab, were analyzed. Cost
effectiveness was calculated in terms of the number of patients
that achieve PASI 75 response with each BA. The base case was
a moderate-to-severe psoriasis patient, with at least 10% BSA
affected, PASI score of at least 12, without infection in the lesions
and eligible for systemic therapy. Time of use of each drug in
Brazil came from a previous Brazilian study and the PASI score
from major studies with each drug from the medical literature.
The local disease management and costs were based on a Delphi
panel according to the private health care perspective. Outcomes
were discounted at 3% annually. RESULTS: In order that all
patients pass all the four treatment lines it took an average time
of 71.3 months; the Brazilian treatment sequence added to fort-
nightly adalimumab, weekly adalimumab, inﬂiximab and eter-
nacept, respectively, generated 529, 799, 879 and 490 patients
achieving PASI 75 and also, respectively, generated R$
129,071,880.38, R$ 257,708,724.48, R$ 132,251,142.76, R$
342,274,532.45 total costs. CONCLUSION: The Brazilian
treatment sequence added to inﬂiximab is a dominant alterna-
tive in relation to that added to weekly adalimumab and eter-
nacept. It also has an acceptable cost-effectiveness ratio in Brazil
in relation to fortnightly adalimumab (R$9092.70).
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OBJECTIVES: To determine the incremental direct health care
and indirect work loss costs associated with patients diagnosed
with atopic dermatitis (AD) from an employer-payer perspective.
METHODS: A de-identiﬁed claims database consisting of 5.1
million covered lives from 31 Fortune 500 self-insured employ-
ers over the period 1998–2005 was used. Each AD patient was
matched with three controls based on age and gender. The
average monthly direct health care costs (i.e., medical & phar-
maceutical costs) were computed for the respective groups. For
the subset of patients who were active employees, the indirect
costs of lost work time were calculated for each group, as mea-
sured by employer disability payments and sick leave time 
multiplied by the employee’s wage. In addition, a multivariate
two-part regression was used to isolate the cost increase attrib-
utable to AD by controlling for age, gender, year, comorbidities,
and organ transplantation. RESULTS: The univariate analysis
showed that the AD patients (N = 13,749) were associated with
higher medical and pharmacy costs than the control group (N =
41,247) by an average of $47 and $42 per person per month,
respectively (medical: $270 vs. $223, p < 0.003; pharmacy: $80
vs. $38, p < 0.0001), bringing the total increase in health care
costs to $88 per person per month ($349 vs. $261, p < 0.0001).
In the subset of active employees, the AD group (N = 1588) was
associated with higher indirect work loss costs of $64 per person
per month ($148 vs. $85, p < 0.0001) than the control group (N
= 3900). For each cost category, a statistically signiﬁcant cost
increase for AD patients was conﬁrmed through the multivari-
ate analysis (adjusted incremental direct cost = $52, p < 0.0001;
adjusted incremental indirect cost = $31, p < 0.0001). CON-
CLUSION: AD was associated with a statistically signiﬁcant
increase in health care and work loss costs. The multivariate
analysis indicated that the total direct and indirect cost increase
was approximately $83 per person per month.
PSK3
THE DIRECT AND INDIRECT COST BURDEN ASSOCIATED
WITH SEBORRHEIC DERMATITIS
Duh MS1, Fowler JF2, Rovba L1, Buteau S1, Pinheiro L1, Lobo F3,
Sung J3, Doyle JJ3, Mallett D4, Kosicki G1
1Analysis Group, Inc, Boston, MA, USA, 2University of Louisville,
Louisville, KY, USA, 3Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA, 4Ingenix Employer Solutions, New Haven, CT, USA
OBJECTIVES: To determine the incremental direct health care
and indirect work loss costs experienced by employer-payers for
patients diagnosed with seborrheic dermatitis (SD). METHODS:
A de-identiﬁed claims database consisting of 5.1 million covered
lives from 31 Fortune 500 self-insured employers over the period
1998–2005 was used. Each SD patient was matched with three
controls based on age and gender. The average monthly direct
health care costs (i.e., medical & pharmaceutical costs) were
computed for the respective groups. For the subset of patients
who were active employees, the indirect costs of lost work time
were calculated for each group, as measured by employer dis-
ability payments and sick leave time multiplied by the employee’s
wage. In addition, a multivariate two-part regression was used
to isolate the cost increase attributable to SD by controlling for
age, gender, year, comorbidities, and organ transplantation.
RESULTS: The univariate analysis showed that the SD patients
(N = 6860) were associated with higher medical and pharmacy
costs than the control group (N = 20,580) by an average of $136
and $62 per person per month, respectively (medical: $412 vs.
$277, p < 0.0001; pharmacy: $139 vs. $76, p < 0.0001), bring-
ing the total increase in health care costs to $198 per person per
month ($551 vs. $353, p < 0.0001). In the subset of active
employees, the SD group (N = 1666) was associated with a
higher indirect work loss cost of $50 per person per month ($132
vs. $82, p < 0.0001) than the control group (N = 4103). For each
cost category, a statistically signiﬁcant cost increase for SD
patients was conﬁrmed through the multivariate analysis
(adjusted incremental direct cost = $62, p = 0.005; adjusted
incremental indirect cost = $44, p = 0.042). CONCLUSIONS:
SD was associated with a statistically signiﬁcant increase in
health care and work loss costs. The multivariate analysis indi-
